Announcements Trials
Browse Landscape

Phase

Phase 2 16Phase 1 4Phase NA 2Phase 3 2Phase 1/2 1

Status

Unknown 3Terminated 1

Sponsor Class

OTHER 3NIH 1

Study Type

Interventional 4

Sponsor

Cancer Type

Other hematologic neoplasm 3Thoracic 1Lymphoid 1

Conditions

Leukemia 3Recurrence 2Lymphoma, Non-Hodgkin 1Lung Neoplasms 1Leukemia, Hairy Cell 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Cyclophosphamide 624pembrolizumab 500Paclitaxel 456Gemcitabine 438Carboplatin 435Cisplatin 418Radiotherapy 380fludarabine 365Nivolumab 340Docetaxel 277Bevacizumab 276Irinotecan 257Magnetic Resonance Spectroscopy 242Fluorouracil 228Dexamethasone 225Specimen Handling 221Capecitabine 218Rituximab 205Cytarabine 201Oxaliplatin 200Ipilimumab 199Temozolomide 197Biopsy 196fludarabine phosphate 194Etoposide 181Lenalidomide 176Doxorubicin 175Leucovorin 173Cetuximab 171Injections 170

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1 × Biological Therapy × Clear all
NCT00098917 2008-01-28

Vaccine Therapy in Treating Patients Who Are Undergoing Surgery for Stage IB, Stage II, or Stage IIIA Non-Small Cell Lung Cancer

National Cancer Institute (NCI)

Phase 1 Terminated
15 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00515892 2007-08-14

NHL

Cambridge Antibody Technology

Phase 1 Unknown
50 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Non-Hodgkin

NCT00462189 2007-04-18

Safety Study of CAT-8015 Immunooxin in Patients With HCL With Advance Disease

Cambridge Antibody Technology

Phase 1 Unknown
40 enrolled
Other hematologic neoplasm

Leukemia, Leukemia, Hairy Cell, Recurrence

NCT00457860 2007-04-17

Safety Study of CAT-8015 Immunotoxin in Patients With CLL, PLL or SLL With Advance Disease

Cambridge Antibody Technology

Phase 1 Unknown
50 enrolled
Other hematologic neoplasm

Leukemia, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡